-
Antiviral API
- Arenavirus
- Cytomegalovirus (CMV)
- Endogenous Metabolite
- Enterovirus (EV)
- Epstein-Barr virus (EBV)
- Filovirus
- HCV Protease
- Hepatitis B Virus (HBV)
- Hepatitis C Virus (HCV)
- Herpes simplex Virus (HSV)
- HIF/HIF Prolyl-Hydroxylase
- HIV Integrase
- HIV Protease
- Human immunodeficiency Virus (HIV)
- Human papillomavirus (HPV)
- Influenza Virus
- Orthopoxvirus
- Others
- Respiratory syncytial Virus (RSV)
- Reverse Transcriptases (RTs)
- SARS-CoV
- Virus Protease
- Antiviral intermediates
Boceprevir
![{PARAM:[Name]}()](https://resource.bocsci.com/structure/394730-60-0.gif)
| Category | HCV Protease |
| CAS | 394730-60-0 |
| Description | An NS3 serine protease inhibitor of hepatitis C virus, for the treatment of HCV infection. |
Product Information
| Synonyms | EBP 520; EBP-520; EBP520; SCH-503034; SCH503034; SCH 503034 trade name: Victrelis. |
| Molecular Weight | 519.687 |
| Molecular Formula | C27H45N5O5 |
| Canonical SMILES | CC1(C2C1C(N(C2)C(=O)C(C(C)(C)C)NC(=O)NC(C)(C)C)C(=O)NC(CC3CCC3)C(=O)C(=O)N)C |
| InChI | InChI=1S/C27H45N5O5/c1-25(2,3)20(30-24(37)31-26(4,5)6)23(36)32-13-15-17(27(15,7)8)18(32)22(35)29-16(19(33)21(28)34)12-14-10-9-11-14/h14-18,20H,9-13H2,1-8H3,(H2,28,34)(H,29,35)(H2,30,31,37)/t15-,16?,17-,18-,20+/m0/s1 |
| InChIKey | LHHCSNFAOIFYRV-DOVBMPENSA-N |
| Purity | 0.98 |
| Density | 1.2±0.1 g/cm3 |
| Solubility | In Vitro: DMSO : 16.67 mg/mL(32.08 mM;Need ultrasonic) In Vivo: 1.Add each solvent one by one:10% DMSO >> 40%PEG300 >> 5%Tween-80 >> 45% saline Solubility: ≥ 1.67 mg/mL (3.21 mM); Clear solution 2.Add each solvent one by one:10% DMSO >> 90% (20%SBE-β-CDin saline) Solubility: 1.67 mg/mL (3.21 mM); Suspended solution; Need ultrasonic 3.Add each solvent one by one:10% DMSO >> 90%corn oil Solubility: ≥ 1.67 mg/mL (3.21 mM); Clear solution |
| Appearance | Off-white to pale yellow solid powder |
| Storage | Powder: -20°C 3 years 4°C 2 years In solvent: -80°C 6 months -20°C 1 months |
| Complexity | 959 |
| Exact Mass | 519.34206955 |
| Index Of Refraction | 1.533 |
| PSA | 150.70000 |
| Target | HCV Protease; HCV; SARS-CoV |
| XLogP3-AA | 3.1 |
